Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRD | O14764 | 3/20 | 0.51 |
| ▸ | GABRA1 | P14867 | 3/20 | 0.51 |
| ▸ | GABRB1 | P18505 | 3/20 | 0.51 |
| ▸ | GABRA5 | P31644 | 3/20 | 0.51 |
| ▸ | GABRA3 | P34903 | 3/20 | 0.51 |
| ▸ | GABRA2 | P47869 | 3/20 | 0.51 |
| ▸ | GABRB2 | P47870 | 3/20 | 0.51 |
| ▸ | GABRA4 | P48169 | 3/20 | 0.51 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.43 |
| ▸ | PGR | P06401 | 1/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.43 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 1/20 | 0.43 |
| ▸ | MLKL | Q8NB16 | 1/20 | 0.42 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30267496 | 1.00 | GABRD (0.51) | GABRDGABRA1GABRB1GABRA5GABRA3 | |
| SCHEMBL21409353 | 0.92 | NR3C1 (0.41) | GABRDGABRA1GABRB1GABRA5GABRA3 | |
| Hydrochloric Acid SCHEMBL31138071 | 0.91 | NR3C1 (0.41) | GABRDGABRA1GABRB1GABRA5GABRA3 | |
| SCHEMBL21408934 | 0.91 | KCNH2 (0.44) | NR3C1PGRSLC6A4KCNH2PDE3B | |
| SCHEMBL25596253 | 0.91 | NR3C1 (0.44) | GABRDGABRA1GABRB1GABRA5GABRA3 | |
| SCHEMBL25904549 | 0.91 | NR3C1 (0.44) | NR3C1PGRSLC6A4KCNH2PDE3B | |
| SCHEMBL24735010 | 0.91 | NR3C1 (0.47) | NR3C1PGRSLC6A4KCNH2PDE3B | |
| SCHEMBL29841507 | 0.91 | NR3C1 (0.47) | NR3C1PGRSLC6A4KCNH2PDE3B | |
| SCHEMBL26949210 | 0.90 | GABRD (0.49) | GABRDGABRA1GABRB1GABRA5GABRA3 | |
| Hydrochloric Acid SCHEMBL29841613 | 0.90 | NR3C1 (0.46) | NR3C1PGRSLC6A4KCNH2PDE3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118754858-A | N- (3- (7H-pyrrolo [2,3-d ] pyrimidin-4-yl) phenyl) benzamide derivatives | 诺华股份有限公司 | 2024-10-11 | — | — | CN | disclosed |
| CN-117964623-A | Targeted protein degradation compound and preparation method and application thereof | 上海领泰生物医药科技有限公司 | 2024-05-03 | — | — | CN | disclosed |
| CN-117917416-A | KRAS G12D degradation agent and preparation method and application thereof | 上海领泰生物医药科技有限公司 | 2024-04-23 | — | — | CN | disclosed |
| CN-111936498-B | N- (3- (7H-pyrrolo [2,3-d ] pyrimidin-4-yl) phenyl) benzamide derivatives | 诺华股份有限公司 | 2024-04-16 | — | — | CN | disclosed |
| CN-115244053-B | Targeted protein degradation compound and preparation method and application thereof | 上海领泰生物医药科技有限公司 | 2024-01-30 | — | — | CN | disclosed |
| US-20230398117-A1 | 3-hydroxy-N-(3-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl)pyrrolidine-1-carboxamide Derivatives | NOVARTIS AG (CH) | 2023-12-14 | — | — | US | disclosed |
| CN-117186108-A | Bruton's tyrosine kinase degradation agent | 诺华股份有限公司 | 2023-12-08 | — | — | CN | disclosed |
| CN-111936501-B | Bruton's tyrosine kinase degradation agent | 诺华股份有限公司 | 2023-09-22 | — | — | CN | disclosed |
| US-20230234936-A1 | COMPOUND FOR TARGETING AND DEGRADING PROTEIN, AND PREPARATION METHOD THEREFOR AND USE THEREOF | LEADINGTAC PHARMACEUTICAL (SHAOXING) CO., LTD. (CN) | 2023-07-27 | — | — | US | disclosed |
| US-20230234936-A1 | COMPOUND FOR TARGETING AND DEGRADING PROTEIN, AND PREPARATION METHOD THEREFOR AND USE THEREOF | LEADINGTAC PHARMACEUTICAL (SHAOXING) CO., LTD. (CN) | 2023-07-27 | — | — | US | disclosed |
| EP-4031247-A1 | BIFUNCTIONAL DEGRADERS AND THEIR METHODS OF USE | Novartis AG (CH) | 2022-07-27 | — | — | EP | disclosed |
| CN-114521196-A | Bifunctional group degradation agent and use method thereof | 诺华股份有限公司 | 2022-05-20 | — | — | CN | disclosed |
| US-20210251996-A1 | 3-hydroxy-N-(3-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl)pyrrolidine-1-carboxamide Derivatives | NOVARTIS AG (CH) | 2021-08-19 | — | — | US | disclosed |
| WO-2021053495-A1 | BIFUNCTIONAL DEGRADERS AND THEIR METHODS OF USE | NOVARTIS AG (CH) | 2021-03-25 | — | — | WO | disclosed |
| EP-3774804-A1 | N-(3-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)PHENYL)BENZAMIDE DERIVATIVES | Novartis AG (CH) | 2021-02-17 | — | — | EP | disclosed |
| EP-3774808-A1 | 3-HYDROXY-N-(3-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)PHENYL)PYRROLIDINE-1-CARBOXAMIDE DERIVATIVES | Novartis AG (CH) | 2021-02-17 | — | — | EP | disclosed |
| US-20210002285-A1 | N-(3-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl)benzamide Derivatives | NOVARTIS PHARMA AG (CH) | 2021-01-07 | — | — | US | disclosed |
| CN-111936501-A | 3-hydroxy-N- (3- (7H-pyrrolo [2,3-d ] pyrimidin-4-yl) phenyl) pyrrolidine-1-carboxamide derivatives | 诺华股份有限公司 | 2020-11-13 | — | — | CN | disclosed |
| WO-2019186358-A1 | 3-HYDROXY-N-(3-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)PHENYL)PYRROLIDINE-1-CARBOXAMIDE DERIVATIVES | NOVARTIS AG (CH) | 2019-10-03 | — | — | WO | disclosed |
| WO-2019186343-A1 | N-(3-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)PHENYL)BENZAMIDE DERIVATIVES | NOVARTIS AG (CH) | 2019-10-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230234936-A1 | COMPOUND FOR TARGETING AND DEGRADING PROTEIN, AND PREPARATION METHOD THEREFOR AND USE THEREOF | IRAK4, IRAK2, IRAK1 | GABRD 3732/4885GABRA1 3511/4885GABRB1 3636/4885 |
| US-20230398117-A1 | 3-hydroxy-N-(3-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl)pyrrolidine-1-carboxamide Derivatives | PAH, PKD1, REN | GABRD 2413/4885GABRA1 2007/4885GABRB1 2343/4885 |
| US-20210251996-A1 | 3-hydroxy-N-(3-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl)pyrrolidine-1-carboxamide Derivatives | PAH, PKD1, REN | GABRD 2413/4885GABRA1 2007/4885GABRB1 2343/4885 |
| US-20210002285-A1 | N-(3-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl)benzamide Derivatives | PAH, PARK7, PKD1 | GABRD 1235/4885GABRA1 883/4885GABRB1 923/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.